vs
Side-by-side financial comparison of ACHIEVE LIFE SCIENCES, INC. (ACHV) and TRINITY BIOTECH PLC (TRIB). Click either name above to swap in a different company.
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the Nasdaq-100 and the S&P 100.
Trinity Biotech PLC develops, manufactures and markets diagnostic test kits and systems for clinical laboratories and point-of-care settings. Its product portfolio covers diabetes management, infectious diseases, cardiac health, autoimmune disorders and coagulation, with core markets across North America, Europe and emerging economies.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 24 | — | $30.5M | ||
| Q3 23 | — | $15.7K | ||
| Q2 23 | — | $15.4K | ||
| Q1 23 | — | $15.7K | ||
| Q2 22 | — | $37.2M | ||
| Q1 22 | — | $25.6K |
| Q2 24 | — | $-10.1M | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q2 22 | — | $-22.0M | ||
| Q1 22 | — | — |
| Q2 24 | — | 36.8% | ||
| Q3 23 | — | 2.1% | ||
| Q2 23 | — | 36.2% | ||
| Q1 23 | — | 38.2% | ||
| Q2 22 | — | 37.0% | ||
| Q1 22 | — | 42.6% |
| Q2 24 | — | -23.2% | ||
| Q3 23 | — | -51.8% | ||
| Q2 23 | — | -12.0% | ||
| Q1 23 | — | -7.8% | ||
| Q2 22 | — | -5.0% | ||
| Q1 22 | — | 12.0% |
| Q2 24 | — | -33.0% | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q2 22 | — | -59.0% | ||
| Q1 22 | — | — |
| Q2 24 | — | — | ||
| Q3 23 | — | $-23.50 | ||
| Q2 23 | — | $-28.60 | ||
| Q1 23 | — | $-50.00 | ||
| Q2 22 | — | — | ||
| Q1 22 | — | $7.10 |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
